Log in to search using one of your social media accounts:

 

AHA 2017 Empagliflozin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - November 14, 2017 Category: Research Source Type: news

Synjardy XR Extended-release Tablets (Empagliflozin and Metformin Hydrochloride Extended-release) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - October 30, 2017 Category: Drugs & Pharmacology Source Type: news

FDA Grants Liraglutide Cardiovascular Events Indication FDA Grants Liraglutide Cardiovascular Events Indication
Liraglutide becomes the second glucose-lowering drug, after empagliflozin, to receive an additional indication for cardiovascular risk reduction.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

Another Diabetes Drug Scores Heart Indication
(MedPage Today) -- Liraglutide follows empagliflozin into cardiovascular approval (Source: MedPage Today Nephrology)
Source: MedPage Today Nephrology - August 25, 2017 Category: Urology & Nephrology Source Type: news

More Evidence Empagliflozin Protects the Kidneys More Evidence Empagliflozin Protects the Kidneys
New data from the EMPA-REG-OUTCOME study provide more evidence of the renoprotective effects of the sodium-glucose co-transporter-2 (SGLT2) inhibitor empagliflozin in patients with type 2 diabetes and cardiovascular disease.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - July 10, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Jardiance ® (empagliflozin) analysis reinforces established safety profile
An analysis of pooled safety data from 15 studies plus 4 extension studies involving more than 12,500 adults with type 2 diabetes demonstrated treatment with Jardiance® (empagliflozin) tablets (10 mg or 25 mg) was well tolerated, with no imbalance in lower limb amputations or bone fractures compared with placebo. The analysis, which includes the EMPA-REG OUTCOME® trial, was published this month in Advances in Therapy.(1) (Source: World Pharma News)
Source: World Pharma News - July 6, 2017 Category: Pharmaceuticals Tags: Featured Boehringer Ingelheim Business and Industry Source Type: news

Boehringer reports positive safety profile of Jardiance for type 2 diabetes
Boehringer Ingelheim has reported a positive safety profile of oral Jardiance (empagliflozin) for the treatment of adults with type 2 diabetes. (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news

June ’s top stories: NIH’s Phase I/II trial for chikungunya, Boehringer & Eli Lilly ’s empagliflozin trial
A new Phase I/II clinical trial of MV-CHIKV for the prevention of the chikungunya virus began enrolment, while Boehringer Ingelheim, along with Eli Lilly and Company, made plans to evaluate empagliflozin in a new clinical outcomes trial for chronic k … (Source: Drug Development Technology)
Source: Drug Development Technology - July 4, 2017 Category: Pharmaceuticals Source Type: news

Jardiance analysis reinforces established safety profile
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 3, 2017 Category: Research Source Type: news

CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes CANVAS: Experts Spar on Canagliflozin Risk/Benefit in Diabetes
Some see the newly revealed cardiovascular benefits as rendering canagliflozin essentially"interchangeable" with empagliflozin, while others view the amputation signal as a deal breaker.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Boehringer and Lilly to assess empagliflozin for chronic kidney disease
Boehringer Ingelheim, in collaboration with Eli Lilly and Company, is set to evaluate empagliflozin in a new clinical outcomes trial to treat patients suffering from chronic kidney disease. (Source: Drug Development Technology)
Source: Drug Development Technology - June 13, 2017 Category: Pharmaceuticals Source Type: news

Empagliflozin to be studied in chronic kidney disease
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - June 12, 2017 Category: Research Source Type: news

Enlightenment Awaits at Paris ESC Heart-Failure Sessions Enlightenment Awaits at Paris ESC Heart-Failure Sessions
Planned for the meeting in La Ville Lumi è re: Fresh insights on the TRUE-AHF, RELAX-AHF-2, and PARADIGM-HF trials, ICDs in nonischemic disease, and how empagliflozin may have earned its CV indication.Heartwire from Medscape (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 26, 2017 Category: Cardiology Tags: Cardiology News Source Type: news

Empagliflozin chronic heart failure outcome trials initiated
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - March 17, 2017 Category: Research Source Type: news

Jardiance cardiovascular death EU label update
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - January 26, 2017 Category: Research Source Type: news

Add-on Empagliflozin May Improve Glycemic Control and Weight Add-on Empagliflozin May Improve Glycemic Control and Weight
When type 2 diabetes is uncontrolled with linagliptin and metformin, adding empagliflozin helps improve glycemic control and weight, researchers say.Reuters Health Information (Source: Medscape General Surgery Headlines)
Source: Medscape General Surgery Headlines - December 28, 2016 Category: Surgery Tags: Diabetes & Endocrinology News Source Type: news

' Incredibly Exciting': Diabetes Drug With CV Benefits'Incredibly Exciting': Diabetes Drug With CV Benefits
The FDA's recent addition of a cardiovascular indication for diabetes drug empagliflozin is a significant milestone in diabetes care, says Dr Anne Peters.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 21, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news

EU Empagliflozin Indication to Be Expanded for CVD Prevention? EU Empagliflozin Indication to Be Expanded for CVD Prevention?
The European Medicines Agency has recommended that the indication for empagliflozin be widened from emphasizing glycemic control to encompassing CVD in type 2 diabetes patients.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 16, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

Trying to Live Normally: ADA's 2017 Focus on Whole Patient Trying to Live Normally: ADA's 2017 Focus on Whole Patient
New American Diabetes Association guidelines also address early type 1 diabetes screening, defining hypoglycemia, new roles for empagliflozin and liraglutide, and vitamin B12 deficiency with metformin use.Medscape Medical News (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - December 16, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology News Source Type: news

CHMP positive opinion Jardiance reduces risk of cv death
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 16, 2016 Category: Research Source Type: news

Jardiance (empagliflozin)
Title: Jardiance (empagliflozin)Category: MedicationsCreated: 12/13/2016 12:00:00 AMLast Editorial Review: 12/13/2016 12:00:00 AM (Source: MedicineNet Diabetes General)
Source: MedicineNet Diabetes General - December 13, 2016 Category: Endocrinology Source Type: news

FDA Approves Synjardy XR (empagliflozin/metformin hydrochloride extended-release) for Adults with Type 2 Diabetes
RIDGEFIELD, Conn. and INDIANAPOLIS, Dec. 12, 2016 /PRNewswire/ -- The U.S. Food and Drug Administration (FDA) has approved Synjardy XR (empagliflozin and metformin hydrochloride extended-release) tablets for adults with type 2 diabetes. When used... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 12, 2016 Category: Drugs & Pharmacology Source Type: news

New diabetes guidelines imminent, Jardiance sales may surge
(Reuters) - Two leading U.S. medical societies are poised in the coming weeks to issue new diabetes treatment guidelines reflecting the lifesaving cardiovascular effects of Eli Lilly's Jardiance in a move expected to drive up the drug's sales. (Source: Reuters: Health)
Source: Reuters: Health - December 9, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Jardiance (Empagliflozin Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 6, 2016 Category: Drugs & Pharmacology Source Type: news

FDA approval Jardiance CV label
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - December 5, 2016 Category: Research Source Type: news

Diabetes Drug Empagliflozin Now Indicated to Reduce CV Mortality Risk (FREE)
By the Editors Empagliflozin (marketed as Jardiance) is now indicated to reduce the risk for cardiovascular death, the FDA announced on Friday.The new … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - December 4, 2016 Category: Primary Care Source Type: news

FDA Approves Empagliflozin for Reducing CVD Death FDA Approves Empagliflozin for Reducing CVD Death
The new indication follows the landmark EMPA-REG trial, the first to show that a diabetes drug could reduce death as well as lower blood glucose.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - December 2, 2016 Category: Cardiology Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA lets Lilly cite Jardiance heart data, shares jump
(Reuters) - U.S regulators said on Friday they would allow Eli Lilly and Co to state that its diabetes drug Jardiance reduces risk of death from heart problems, lifting company shares almost 3 percent and potentially giving a strong boost to the drug's future sales. (Source: Reuters: Health)
Source: Reuters: Health - December 2, 2016 Category: Consumer Health News Tags: healthNews Source Type: news

Jardiance Wins CV Prevention Indication
(MedPage Today) -- FDA approves claim that diabetes drug reduces cardiovascular death risk (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - December 2, 2016 Category: American Health Source Type: news

Empagliflozin Wins CV Prevention Indication
(MedPage Today) -- FDA approves claim that SGLT2 inhibitor reduces cardiovascular death risk (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - December 2, 2016 Category: Cardiology Source Type: news

FDA approves Jardiance to reduce cardiovascular death in adults with type 2 diabetes
The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular disease. (Source: Food and Drug Administration)
Source: Food and Drug Administration - December 2, 2016 Category: American Health Source Type: news

FDA Approves Jardiance (empagliflozin) to Reduce Cardiovascular Death in Adults with Type 2 Diabetes
December 2, 2016 -- The U.S. Food and Drug Administration today approved a new indication for Jardiance (empagliflozin) to reduce the risk of cardiovascular death in adult patients with type 2 diabetes mellitus and cardiovascular... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - December 2, 2016 Category: Drugs & Pharmacology Source Type: news

Empagliflozin cost effective for T2DM, reduces CV event rate
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - November 30, 2016 Category: Drugs & Pharmacology Source Type: news

Jardiance ® (empagliflozin) consistently reduced the risk of cardiovascular death in adults with type 2 diabetes regardless of the type of cardiovascular disease at baseline
(Source: Boehringer Ingelheim Press Releases)
Source: Boehringer Ingelheim Press Releases - November 12, 2016 Category: Research Source Type: news

EMPA-REG: Good News for Kidneys, Too EMPA-REG: Good News for Kidneys, Too
The positive effects of empagliflozin on renal disease are discussed by Dr Christoph Wanner, one of the lead authors of the EMPA-REG OUTCOME trial.Medscape Diabetes & Endocrinology (Source: Medscape Diabetes Headlines)
Source: Medscape Diabetes Headlines - November 1, 2016 Category: Endocrinology Tags: Diabetes & Endocrinology Commentary Source Type: news

New Data on Empagliflozin in Treating Diabetic Kidney Disease New Data on Empagliflozin in Treating Diabetic Kidney Disease
Dr Desai discusses a new study exploring the long-term renal effects of empagliflozin and whether it could protect kidney function in patients with diabetes and chronic kidney disease.Medscape Nephrology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - September 29, 2016 Category: Consumer Health News Tags: Nephrology Viewpoint Source Type: news

Empagliflozin CV Benefit Unaffected by HF Burden: EMPA-REG Empagliflozin CV Benefit Unaffected by HF Burden: EMPA-REG
In a clinical-trial update, researchers look into empagliflozin effects on type 2 diabetes patients who have heart failure at study baseline, incident heart failure during the trial, or not at all.Heartwire from Medscape (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 2, 2016 Category: Consumer Health News Tags: Cardiology News Source Type: news

Synjardy (Empagliflozin and Metformin Hydrochloride Tablets) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - August 2, 2016 Category: Drugs & Pharmacology Source Type: news

Jardiance < sup > ® < /sup > (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease
Jardiance ® (empagliflozin) significantly reduced the risk of progressive kidney disease in adults with type 2 diabetes with established cardiovascular disease (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

New Jardiance < sup > ® < /sup > (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes
New Jardiance ® (empagliflozin) data show that reduced risk for cardiovascular (CV) death was consistent across age groups in adults with type 2 diabetes (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Jardiance < sup > ® < /sup > (empagliflozin) to be studied for the treatment of people with chronic heart failure
Jardiance ® (empagliflozin) to be studied for the treatment of people with chronic heart failure (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Phase III data show investigational compound empagliflozin reduced blood glucose in adults with Type 2 Diabetes treated with basal insulin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Phase III data show significant reduction in blood glucose with investigational compound empagliflozin added to metformin or metformin plus sulphonylurea in adults with Type 2 Diabetes
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Jardiance < sup > ® < /sup > demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events
Jardiance ® demonstrated cardiovascular (CV) risk reduction in people with type 2 diabetes at high risk for CV events (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Empagliflozin/metformin demonstrates reductions in blood glucose in data presented at ADA
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

New Jardiance < sup > ® < /sup > (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline
New Jardiance ® (empagliflozin) data show improved CV outcomes regardless of heart failure status at baseline (Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Type 2 Diabetes: CHMP recommends empagliflozin* for approval
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Boehringer Ingelheim and Eli Lilly and Company present efficacy and safety data on linagliptin and investigational compound, empagliflozin in various diabetes subpopulations
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news

Pooled analysis data showed improvements in glycaemic parameters, body weight and blood pressure with investigational agent empagliflozin in adults with Type 2 Diabetes
(Source: Boehringer Ingelheim Corporate News)
Source: Boehringer Ingelheim Corporate News - July 25, 2016 Category: Research Source Type: news